E 21R

Drug Profile

E 21R

Alternative Names: E21R

Latest Information Update: 19 Mar 2007

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Hanson Centre for Cancer Research
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants; Granulocyte macrophage colony stimulating factor antagonists; Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Cancer; Chronic myelomonocytic leukaemia; Rheumatoid arthritis

Most Recent Events

  • 01 Sep 2003 E 21R is available for licensing (http://www.bresagen.com.au)
  • 11 Apr 2003 BresaGen has begun discussions with a major pharmaceutical company for collaborative development of E 21R
  • 11 Apr 2003 Discontinued - Phase-II for Chronic myelomonocytic leukaemia in Australia (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top